Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.
A SchraderG CrispatzuS OberbeckP MayerS PützerJ von JanE VasyutinaK WarnerN WeitN PflugT BraunEmma I AnderssonB YadavA RiabinskaB MaurerM S Ventura FerreiraF BeierJ AltmüllerM LanasaC D HerlingT HaferlachS StilgenbauerG HopfingerMartin PeiferT H BrümmendorfP NürnbergK S J Elenitoba-JohnsonS ZhaM HallekRichard H MorigglH C ReinhardtMarc-Henri SternS MustjokiS NewrzelaP FrommoltM HerlingPublished in: Nature communications (2018)
T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences in 111 well-characterized patients. Besides prominent signatures of T-cell activation and prevalent clonal variants, we also identify novel hot-spots for CN variability, fusion molecules, alternative transcripts, and progression-associated dynamics. The overall lesional spectrum of T-PLL is mainly annotated to axes of DNA damage responses, T-cell receptor/cytokine signaling, and histone modulation. We formulate a multi-dimensional model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression with damaging ATM aberrations as initiating core lesions. The effects imposed by TCL1 cooperate with compromised ATM toward a leukemogenic phenotype of impaired DNA damage processing. Dysfunctional ATM appears inefficient in alleviating elevated redox burdens and telomere attrition and in evoking a p53-dependent apoptotic response to genotoxic insults. As non-genotoxic strategies, synergistic combinations of p53 reactivators and deacetylase inhibitors reinstate such cell death execution.
Keyphrases
- dna damage
- copy number
- dna methylation
- cell death
- gene expression
- dna repair
- mitochondrial dna
- genome wide
- oxidative stress
- end stage renal disease
- dna damage response
- ejection fraction
- lymph node metastasis
- chronic kidney disease
- newly diagnosed
- cancer therapy
- squamous cell carcinoma
- signaling pathway
- patient reported outcomes
- artificial intelligence
- anti inflammatory
- machine learning
- pi k akt